Arcus Biosciences

At the forefront of designing novel combination medicines in the pursuit of cures for people living with cancer. View our guidelines:

[Arcus Biosciences @arcusbio]

🔔 NEWS: We announced a clinical trial collaboration and supply agreement with @BMSnews to evaluate casdatifan, our investigational HIF-2a inhibitor, in combination with a PD-L1/VEGF-A bispecific immunomodulator in the Phase 1/2 ROSETTA RCC-208 trial in advanced #KidneyCancer. Read more: https://t.co/UJhQjmlimW

“HIF-2a inhibition, PD-L1 and VEGF-A blockade are validated mechanisms in the treatment of kidney cancer with a strong biologic rationale for combination. This strategic collaboration with BMS is a top priority for Arcus in order to potentially deliver an additional effective TKI-free option in the first-line setting.”

-Terry Rosen, Ph.D.
Chief Exective Officer
Arcus Biosciences

[Arcus Biosciences @arcusbio]

We’re reporting our first-quarter financial results and an update on our clinical-stage pipeline: https://t.co/9UofY2lWcn

[Arcus Biosciences @arcusbio]

We published safety, biomarker, and clinical outcome data in @NatureMedicine from the Phase 1b study of our investigational CD73 inhibitor.

This research underscores a potential novel approach to treating metastatic #PancreaticCancer for which new treatment options are critically needed. Explore the research: https://t.co/aVWNINHzBm

+++

“Investigating new approaches like CD73 inhibition with a small molecule is a critical step in exploring how targeting adenosine, a key driver of immune suppression, might ultimately make a meaningful impact on patient care. For people with pancreatic cancer, the unmet need for new treatment options is profound. These findings support CD73 as a therapeutic target in pancreatic cancer and we look forward to seeing the results of the Phase 3 PRISM-1 study in early 2027.”

Zev A. Wainberg, M.D., MSc
Co-Director of the GI Oncology Program at University of California Los Angeles and a principal investigator of the ARC-8 trial.

[Uromigos @Uromigos]

Uromigos Unsung Hero poster award. Casdatifan continues to show activity and some biomarkers emerging…

[Arcus Biosciences @arcusbio]

We're reporting our fourth-quarter and full-year financial results as well as an update on our clinical-stage pipeline: https://t.co/v9ZV3elkp7

[Arcus Biosciences @arcusbio]

🔔 NEWS: Today we announced an update on our Phase 3 STAR-221 study evaluating domvanalimab plus zimberelimab and chemotherapy. Read more about this news and our future R&D focus: https://t.co/lM5zuHhYBe

[The Journal of Immunology @J_Immunol]

In this #TopRead article, Dr. Christine Bowman and her team at @arcusbio provide a mechanistic rationale for CD39 inhibition to promote antitumor immunity via the enhancement of eATP-driven myeloid cell activation of T cells. Learn more in The JI: https://t.co/VsS6XGVy19.

[Arcus Biosciences @arcusbio]

We’re reporting our third-quarter financial results and an update on our clinical-stage pipeline. https://t.co/CazJTw2qJ1

[Arcus Biosciences @arcusbio]

We are pleased to announce the fifth option exercise by Taiho to an Arcus program for an exclusive license to our investigational HIF-2a inhibitor for the treatment of #KidneyCancer, in Japan and certain territories in Asia. Read about this collaboration: https://t.co/pZMBZHTkfD

[Arcus Biosciences @arcusbio]

Today at #ESMO25 and published in @NatureMedicine, we shared new Phase 2 data from our EDGE-Gastric study.

🔗 Learn more about our latest data in GI cancers: https://t.co/zZvTMLuMKZ

[Arcus Biosciences @arcusbio]

First overall survival data from our Phase 2 study of investigational anti-TIGIT domvanalimab plus investigational anti-PD-1 zimberelimab and chemotherapy in #StomachCancer will be presented in an oral session at the #ESMO25 Congress. Read more: https://t.co/3U2tip3ZG4

[Arcus Biosciences @arcusbio]

Today at our investor event, we’re pleased to announce new data for our HIF-2a inhibitor for the treatment of metastatic #kidneycancer & the expansion of our research programs into #autoimmune & #inflammatory diseases. Read more and tune into the webcast: https://t.co/9lHqkqCv3t

[Arcus Biosciences @arcusbio]

Two recently published clinical and preclinical studies characterize the pharmacological properties of our investigational HIF-2α inhibitor for kidney #cancer.

Read more about the results: https://t.co/KfzmLdwK7m @BritPharmSoc

[Arcus Biosciences @arcusbio]

We’re reporting our second-quarter financial results and an update on our clinical-stage pipeline. https://t.co/foBsqU23an

[Arcus Biosciences @arcusbio]

We are thrilled to announce the U.S. FDA has granted Orphan Drug Designation to our investigational small molecule CD73 inhibitor quemliclustat, for the treatment of #PancreaticCancer, a rare disease which has seen few treatment advancements over the past 30 years. Learn more: https://t.co/QpJDElLhgN

[Arcus Biosciences @arcusbio]

The first combination data for our HIF-2a inhibitor for the treatment of #KidneyCancer were presented today in an oral session at #ASCO25. Read more about the data and our rapidly advancing development program for casdatifan: https://t.co/8o8txxU1dm

[Arcus Biosciences @arcusbio]

We’re reporting our first-quarter financial results and an update on our clinical-stage pipeline. https://t.co/Y6Pv4h6vPU

[Arcus Biosciences @arcusbio]

First combination data for casdatifan, our HIF-2a inhibitor for the treatment of metastatic #KidneyCancer, will be presented in an oral session at the #ASCO25 Annual Meeting. Read more about this news: https://t.co/siya77MANy